CAB is an integrase inhibitor that is currently in Phase 2 clinical trials for the treatment
and prevention of human immunodeficiency virus-1 (HIV-1) infection. RIF, a rifamycin used
for treatment of tuberculosis (common co-infection in HIV-infected subjects), is a known
inducer of uridine diphosphate (UDP)-glucuronosyltransferases (UGTs) and Cytochrome P450 3A4
(CYP3A4). CAB is primarily metabolized via UGT1A1 and UGT1A9, thus a drug interaction
between CAB and RIF is possible. This study will be a phase I, single-center, open label,
fixed-sequence cross-over study to compare the single dose PK of CAB oral 30 milligrams (mg)
when co-administered with RIF 600 mg once daily at steady-state to those of CAB oral 30 mg
administered alone. Fifteen subjects are planned to be enrolled to obtain 12 evaluable
subjects for this study.
- Males and females between 18 and 65 years of age inclusive, at the time of signing
the informed consent.
- Healthy as determined by a responsible and experienced physician, based on a medical
evaluation including medical history, physical examination, laboratory tests and
- Body weight >=50 kilogram (kg) and body mass index (BMI) within the range 18.5 - 31.0
kg/meter square (m^2) (inclusive).
- Male or female - A female subject is eligible to participate if she is not pregnant
(as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not
lactating, and at least one of the following conditions applies: a) Non-reproductive
potential defined as: Pre-menopausal females with one of the following [for this
definition, "documented" refers to the outcome of the investigator's/designee's
review of the subject's medical history for study eligibility, as obtained via a
verbal interview with the subject or from the subject's medical records]: Documented
tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up
confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral
Oophorectomy; b) Postmenopausal defined as 12 months of spontaneous amenorrhea [in
questionable cases a blood sample with simultaneous follicle stimulating hormone
(FSH) and estradiol levels consistent with menopause >40 milli-international units
per mililiter (MIU/mL) and estradiol <40 picogram/milliliter (pg/mL) (<147
picomoles/liter [pmol/L]) is confirmatory]; c) Reproductive potential and agrees to
follow one of the options listed in the GlaxoSmithKline (GSK) Modified List of Highly
Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP)
requirements from 30 days prior to the first dose of study medication and until after
the last dose of study medication and completion of the follow-up visit.
- Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the consent form and in the protocol.
- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1x upper limit
of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is
fractionated and direct bilirubin <35%).
- Current or chronic history of liver disease, or known hepatic or biliary
abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- History of clinically significant cardiovascular disease including: a) Exclusion
criteria for screening ECG (a single repeat is allowed for eligibility
determination): Heart rate <45 and >100 beats per minute for male subjects and <50
and >100 beats per minute for female subjects, QRS duration >120 millisecond (msec),
and QT interval corrected by Fridericia's formula (QTcF) >450 msec; b) Evidence of
previous myocardial infarction (pathologic Q waves, S-T segment changes (except early
repolarization); c) History/evidence of symptomatic arrhythmia, angina/ischemia,
coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary
angioplasty (PCTA) or any clinically significant cardiac disease; d) Any conduction
abnormality (including but not specific to left or right complete bundle branch
block, atrioventricular (AV) block [2nd degree (type II) or higher], Wolf Parkinson
White [WPW] syndrome) which in the opinion of the principal Investigator and GSK
Medical Monitor, will interfere with the safety for the individual subject; e) Sinus
pauses >3 seconds; f) Any significant arrhythmia which, in the opinion of the
principal Investigator and GSK Medical Monitor, will interfere with the safety for
the individual subject; g) Non-sustained (>=3 consecutive ventricular ectopic beats)
or sustained ventricular tachycardia.
- Subjects must abstain from taking prescription or non-prescription drugs (including
vitamins and dietary or herbal supplements), within 7 days (or 14 days if the drug is
a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
dose of study medication until completion of the follow-up visit, unless in the
opinion of the Investigator and sponsor the medication will not interfere with the
- History of regular alcohol consumption within 6 months of the study defined as: An
average weekly intake of >14 drinks for males or >7 drinks for females. One drink is
equivalent to 12 grams of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of
wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- A history of regular use of tobacco, or nicotine-containing products within 30 days
prior to screening.
- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or Medical
Monitor, contraindicates their participation.
- Presence of Hepatitis B surface antigen (HBsAg), positive Hepatitis C antibody test
result at screening or within 3 months prior to first dose of study treatment.
Hepatitis B core antibody (HBcAb) with negative hepatitis B surface antibody should
also be excluded.
- A positive pre-study drug/alcohol screen.
- A positive test for HIV antibody.
- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.
- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first